Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
Signatera in CRC surveillance
Data on >
Signatera Genome in rectal cancer
An analysis will be presented from the MD Anderson INTERCEPT study (n=31) that used serial Signatera Genome testing in patients with locally advanced rectal cancer after neoadjuvant therapy. Results demonstrated
Economic utility of Signatera-guided therapy in adjuvant CRC
A budget impact model from BUPA, a multinational health insurance provider with over 60 million customers, will outline a
“We’re excited to present these new findings that continue to support the utility of Natera’s products across GI cancers,� said Adham Jurdi, M.D., senior medical director of oncology at Natera. “These data highlight our commitment to improving outcomes and driving innovation in MRD detection.�
Full list of data featuring Natera’s technology at ESMO GI:
July 4, 16:40-16:50 CET | FPN: 20 | Signatera (Oral Presentation)
Presenter: Arvind Dasari, M.D., MS
Clinical utility of including circulating tumor DNA (ctDNA) monitoring in standard of care (SoC) colorectal cancer (CRC) surveillance
July 4, 16:50-17:00 CET | FPN: 30 | Signatera (Oral Presentation)
Presenter: Hideaki Bando, M.D.
Association of ctDNA Clearance with Disease-Free Survival and Safety and Quality of Life from ctDNA-Directed Therapy: Findings from the
July 4, 15:30-16:30 CET | FPN: 102P | Signatera (Poster Presentation)
Presenter: Christos Mikropoulos, MBBS, MSc, M.D. (Res), MRCP, FRCR
Direct cost of healthcare analysis of Signatera ctDNA testing in the adjuvant setting for a hypothetical cohort of stage II and stage III colorectal cancer (CRC) patients: a
July 4, 15:30-16:30 CET | FPN: 243P | Signatera Genome (Poster Presentation)
Presenter: Arvind Dasari, M.D., MS
Clinical performance of Signatera Genome assay in a sub-cohort of locally advanced rectal cancer (LARC) patients (pts) in the MD Anderson INTERCEPT program
July 4, 15:30-16:30 CET | FPN: 93P | Tissue-free MRD (Poster Presentation)
Presenter: Yoshiaki Nakamura, M.D., Ph.D.
Clinical validation of a methylation-based, tissue-free colorectal cancer test for the detection of molecular residual disease by circulating tumor DNA
July 4, 15:30-16:30 CET | FPN: 89P | Early Cancer Detection (Poster Presentation)
Presenter: John P.Y. Shen, M.D.
Development of methylation-based biomarkers to predict metastases, treatment effect, and microsatellite status in colorectal cancer
Notes
*Circulating tumor DNA
About Natera
Natera� is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in “Risk Factors� in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and .
View source version on businesswire.com:
Investor Relations: Mike Brophy, CFO, Natera, Inc., [email protected]
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., [email protected]
Source: Natera, Inc.